Solomon SD, Ostrominski JW, Wang X et al (2024) Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
#GoogleAds #HealthcareMarketing #DigitalHealth #Pharmacy #Ecommerce To view or add a comment, sign in After months of screaming that compounding pharmacies do not report adverse events (by the way, 503Bs are legally required to report adverse events), Novo received a FDA Warning Letter this morning for not reporting adverse events
The CagriSema dosing protocols provide a reference point for researchers designing their own cagrilintide combination studies
In early 2024, AOM semaglutide prescriptions were steadily increasing
This drug may also cause side effects, including nausea/vomiting, diarrhea, constipation, headache and dyspepsia